clinical trial · NCT05103332
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2)
HypertensionIndapamideAmlodipineOlmesartanPlaceboZilebesiran
brief summary
The purpose of this study is to evaluate the effect of zilebesiran on systolic and diastolic blood pressure and to characterize the pharmacodynamic (PD) effects and safety of zilebesiran as add-on therapy.
started
Nov 5, 2021
primary completion
Dec 11, 2023
completion
Sep 13, 2024
last updated
Nov 3, 2025
official title
A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Zilebesiran Used as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol